product name Pergolide Mesylate
Description: Pergolide Mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist. It is used in some countries for the treatment of Parkinsons disease. Pergolide mesylate functions as an agonist at the dopamine D2, D1 and serotonin 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT2C receptors. It may possess agonist activity at other dopamine receptor subtypes as well, similar to cabergoline.
References: Science. 1979 Sep 14;205(4411):1151-3; Br Med J (Clin Res Ed). 1983 Apr 9; 286(6372): 1177–1179.
410.59
Formula
C19H26N2S.CH4O3S
CAS No.
66104-23-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 10 mg/mL (24.35 mM)
Water: 82 mg/mL (199.71 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
LY127809
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19414692
| In Vitro |
In vitro activity: Pergolide mesylate (trade name Permax) is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinsons disease. Pergolide mesylate functions as an agonist at the dopamine D2, D1 and serotonin 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT2C receptors. It may possess agonist activity at other dopamine receptor subtypes as well, similar to cabergoline. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Pergolide mesylate decreases plasma prolactin concentrations. The weak agonist activity of pergolide at D1 receptors somewhat alters its clinical and side effect profile in the treatment of Parkinsons disease. The drug is in decreasing use, as it is reported to be associated with a form of heart disease called cardiac fibrosis. The use of pergolide or cabergoline is associated with a significantly increased risk of newly diagnosed cardiac-valve regurgitation. |
| Animal model | |
| Formulation & Dosage | |
| References | Science. 1979 Sep 14;205(4411):1151-3; Br Med J (Clin Res Ed). 1983 Apr 9; 286(6372): 1177–1179. |
